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A blocked recombinase polymerase amplification (blocked-RPA) approach has been 16 
developed for the enrichment of mutated templates in heterogeneous specimens as 17 
tumor tissues. This isothermal amplification technique opens alternative solutions for 18 
meeting the technological demand of physician office laboratories. Herein, the detection 19 
of mutations in PIK3CA gene, such as p.E545K, and p.H1047L, is presented. The main 20 
element was an oligonucleotide (dideoxycytidine functionalized at 3’-end) which matched 21 
with wild-type sequence in the target locus. The amplification was performed operating 22 
at 37 ºC during 40 min. The results demonstrated that the competition between the 23 
upstream primer and the blocker reduced the percentage of amplified wild-type allele, 24 
making the detection of the present mutation easier. 25 
For mutation discrimination, a fast hybridization assay was performed in microarray 26 
format on plastic chip and colorimetric detection. This approach enabled the reliable 27 
discrimination of specific mutations against a background of up to 95% wild-type DNA. 28 
The applicability of the method, based on the combination of blocked-RPA and low-cost 29 
chip hybridization, was successfully proven for the genotyping of various cancer cell lines 30 
as well as tumor tissues. The assignations agreed with those provided by next-31 
generation sequencing. Therefore, these investigations would support a personalized 32 
approach to patient care based on the molecular signature of human cancers. 33 
 34 
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Neoplastic diseases are currently the leading cause of morbidity and mortality in 39 
developed countries, making cancer a public health problem of the first magnitude. The 40 
success of anticancer therapies depends on the correct assignation of disease subtype. 41 
Therefore, the detection of tumour biomarkers is important for the application of a 42 
personalized medicine [1,2]. Somatic mutations on oncogenes are excellent predictive 43 
biomarkers since the response to a particular line of treatment can be anticipated, 44 
reducing the adverse effects and improving efficiency [3]. They also can be prognostic 45 
biomarkers enabling the prediction of disease progression. 46 
Several molecular techniques can be applied for knowing the mutational status of 47 
oncogene hotspots. In a DNA extract from patient sample (solid tissues and body fluids), 48 
the mutant variant is found in a low proportion compared to wild-type variant. This 49 
scenario presents an analytical challenge because wild-type variant can exhaust 50 
essential reagents and/or mask the mutant signal during detection assays [4]. Next-51 
generation sequencing instruments holds great promise for point mutation detection, but 52 
currently, this technology is available in few health centers and clinics. The alternative 53 
solutions are based on introducing an enrichment method combined to more simple 54 
detection techniques. Particularly interesting are PCR-based methods proposed for a 55 
selective (or quasi-selective) amplification of minority alleles and mutations. These 56 
include the use of allele-specific primers to selectively initiate the amplification of the 57 
mutated genotype [5,6]; addition of oligonucleotide clamps to preferentially inhibit primer 58 
extension on wild type targets [7-9]; and control of temperature thermocycling to favor 59 
the preferential denaturation of mutant targets [10]. The differential behavior between 60 
wild-type and mutant variants are obtained using real-time or end-point amplification, 61 
fluorescence being the main detection principle. Most of described methods are able to 62 
detect the presence of mutation in the selected hotspot, but they do not provide 63 
information about their identification. 64 
Herein, we developed an in vitro method based on a blocked isothermal amplification as 65 
enrichment technique for analyzing point mutations in PIK3CA gene 66 
(phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha) as oncogene 67 
model. This gene codifies important cell membrane element and second messenger 68 
involved in cell signaling. The mutation has been located in human cancer as colorectal, 69 
breast, glioblastoma, gastric, ovary, lung, and skin [11,12]. There is an important basic 70 
and clinical research for understanding the impact of mutation on cancer cell growth, 71 
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survival, motility, and metabolism [13]. Additionally, novel inhibitor drugs are targeting 72 
this mutant protein [14].  73 
Isothermal amplifications are revolutionizing the development of point-of-care testing due 74 
to their capability for the integration in portable, inexpensive instruments or devices 75 
[15,16]. Loop-mediated isothermal amplification (LAMP) is the most cited alternative to 76 
PCR. Their allele-specific option has displayed excellent results in the detection of a 77 
specific point mutation in EGFR gene [17], BRAF gene [18] and KRAS gene [19]. Rolling 78 
circle amplification (RCA) and recombinase polymerase amplification (RPA) have been 79 
used for the detection of point mutation [20, 21]. In our previous research, the genotyping 80 
of a single-point polymorphism was achieved using allele-specific primers for 81 
discriminating perfect-match and mismatch allele. In the current study, a new strategy is 82 
addressed for improving sensitivity, based on the addition of a blocking oligonucleotide 83 
to reduce the amplification of wild-type variant. Then, the presence of mutated variants 84 
can be established. Furthermore, an allele-selective hybridization is proposed in order to 85 
discriminate between different nucleotide changes. As proof of concept, the selected 86 
format involves a plastic chip as analytical platform and colorimetric imagining as 87 
detection approach. Microarrays represent an accurate tool for parallel identification of 88 
multiple markers, suitable for routine analysis in medical diagnostics [22].  89 
 90 
EXPERIMENTAL 91 
Material and reagents 92 
Oligonucleotide sets were designed for the analysis of two important hotspots in PIK3CA 93 
gene (Table SI.1). In the helicase domain of exon 9, the most frequent mutations are in 94 
codon 542 (p.E542K) and codon 545 (p.E545K, p.E545A, and p.E545G). In the kinase 95 
domain of exon 20, they are in codon 1047 (p.H1047R and p.H1047L). Thermodynamic 96 
parameters were calculated for inducing the selective recognition of target regions [23]. 97 
The list of used oligonucleotides, supplied by Eurofins, is included as Supplementary 98 
Material (Table SI.2). 99 
The reagents used for genomic DNA amplification were TwistAmp Basic RPA kit 100 
(TwistDx, UK). For microarray detection, the printing buffer composition was (2-(N-101 
morpholino)ethanesulfonic acid at 0.1 M, 1-ethyl-3-(3-dimethylaminopropyl) 102 
carbodiimide at 20 mM, glycerol 10% (pH 5.5). The hybridization buffer was saline-103 
sodium citrate (SSC) 2×: sodium chloride at 150 mM, sodium citrate at 15 mM, 104 
formamide 20% (pH 7.0). Hybridization washing buffer was a solution with NaCl 15 mmol 105 
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L-1, trisodium citrate 1.5 mmol L-1. Developing buffer was a phosphate buffered saline 106 
solution (PBS-T) containing 137 mM NaCl, 12 mM phosphate, 2.7 mM KCl, 0.05% 107 
Tween 20 (pH 7.4).  108 
The hybridization chips were prepared by immobilizing the allele-specific probes on 109 
rectangular slides (25 mm  75 mm). For covalent anchoring of probes, polycarbonate 110 
surface was activated by UV-ozone incubation (model FHR.Clean.150-Lab, FHR, 111 
Germany) using UV lamps (50 mW cm-1) at 254 nm. After, the chips were immersed in 112 
a solution of NaOH 1M at 60 C, washed with distilled water and dried. The dispensation 113 
of amine-DNA probes in printing buffer on the modified surface was performed by non-114 
contact array printer equipment (AD1500, Biodot). The printing volume drop was 40 nL. 115 
Six arrays were printed per chip, including 4 replicates per target probe and controls. The 116 
chips were incubated for 1 hour, washed with PBS-T and water, dried and stored at 4 C 117 
until use. 118 
 119 
Samples and DNA extraction 120 
Patients and several volunteers were recruited for the present study according to ethics 121 
and with informed consents. Genomic DNA was extracted from three 5-μm thick FFPE 122 
sections using Deparaffinization Solution and the GeneRead DNA FFPE Kit (Qiagen, 123 
Hilden, Germany) according to manufacturer’s protocol. This isolation kit contains uracil-124 
DNA glycosylase (UDG) that leads to the reduction of C>T sequence artefacts. Buccal 125 
cells were collected by rolling the swab (Catch-All sample collection swab, Epicenter) on 126 
the inside of the cheek. DNA extraction was performed using the PureLink Genomic DNA 127 
Mini Kit (Invitrogen). Briefly, the swab was incubated with Proteinase K, RNAse and 128 
lysate buffer. The purification was performed by using a spin column-based 129 
centrifugation procedure. Human cell lines SK-N-AS (ATCC CRL-2137) and HCT 116 130 
(ATCC CCL-247) were used as native (wild type) and heterozygous 131 
(p.H1047R/c.3140A>G) controls, respectively. In these cases, DNA extraction was 132 
performed using PureLink kits (Invitrogen).  133 
In addition, the assay included a negative control (DNA from Salmonella Typhimurium). 134 
The concentration of the DNA extracts (ng µL-1) was obtained by spectrophotometry 135 
using NanoDrop 2000c, and by fluorimetry using Qubit dsDNA HS Assay Kit 136 
(ThermoFisher Scientific). 137 
 138 
PCR amplification 139 
6 
 
PCR amplification in single format was performed for each target hotspot in PIK3CA 140 
gene (exon 9 or exon 20). Each reaction mixture contained 1 × DNA polymerase buffer, 141 
3 mM of MgCl2, 200 M of each deoxynucleotide triphosphate, 200 nM of upstream 142 
primer and downstream digoxigenin-labeled primer, 4 ng of genomic DNA, and 1 unit of 143 
DNA polymerase (Biotools, Madrid, Spain). In certain experiments, a blocking 144 
oligonucleotide complementary to wild-type variant was added to each mixture (10 nM – 145 
400 nM). The reaction was performed in thermocycler (United Nations, VWR) under the 146 
following conditions: initial denaturation cycle of 95 C for 5 min, 35 cycles of 147 
denaturation at 95 C for 30 s, annealing 57 C for 30 s and elongation at 72 C for 60 s, 148 
finally one cycle extension at the end for 5 min.  149 
 150 
RPA amplification 151 
RPA amplification in single format was performed for each target hotspot in PIK3CA gene 152 
(exon 9 or exon 20). The reaction mixtures (12.5 µL) were prepared with rehydrated 153 
buffer, 14 mM of magnesium acetate, 480 nM of upstream primer and downstream 154 
digoxigenin-labeled primer, 50 nM of blocking agent, 4 ng of genomic DNA, and the 155 
enzyme pellet. The reaction mixtures for conventional RPA did not contained the 156 
oligonucleotide complementary to wild-type variant. The heating system used was a 157 
thermocycler (United Nations, VWR) at 37 ºC for 40 min. 158 
 159 
Gel electrophoretic detection 160 
The RPA amplicons were cleaned for being visualized using agarose gel electrophoresis. 161 
Two methods were compared, the first being based on silica-gel membrane adsorption 162 
(PCR purification kit, Jena Bioscience, Germany). The RPA products, mixed with binding 163 
buffer and isopropanol, was transferred to the activated column and centrifuged at 164 
10.000g for 30 s. After washing the column twice, the elution fraction was collected in 165 
distilled water. The second method was based on denaturation protocol. The RPA 166 
products were incubated at 65 °C in dry bath (model FB 15103, Fisher Scientific) for 10 167 
min. After centrifugation at 10.000g for 20 s, the supernatant fraction was collected.  168 
The electrophoretic separation was conducted in agarose gel 3 %. Amplification 169 
solutions were mixed with loading buffer and transferred to gel wells. After separation at 170 
110 V, fluorescent dye (Realsafe Nucleic acid Staining Solution 2x, Real Lab.) was 171 
incubated for 30 min. Gel images were captured using a smartphone Iphone 7 and 172 




Colorimetric chip detection  175 
The RPA products were detected and identified by a hybridization assay using allele 176 
selective probes immobilized on polycarbonate chips. Amplified products (5 L) were 177 
mixed with 45 L of hybridization buffer, heated (95 C, 5 min) and dispensed onto 178 
sensing arrays to perform the simultaneous analysis of 6 samples (four probe replicates). 179 
After incubation (37 C, 60 min), the arrays were rinsed with progressive dilutions of 180 
hybridization washing buffer. To develop the probe-product duplex, an immunoreaction 181 
was used. PBST solution with 1:2500 monoclonal anti-Dig antibody (Abcam) and 1:400 182 
monoclonal antisheep-HRP antibody in PBST, was dispensed (room temperature, 30 183 
min). As HRP-substrate, 3,3’,5,5’-tetramethylbenzidine solution (ep(HS)TMB-mA, SDT 184 
Reagents) was selected, generating a solid deposit.  185 
Chips were directly scanned (Epson Perfection 1640SU office scanner), producing gray-186 
scale images (Tagged Image File Format, color depth 16 bit, scale 0-65535). The optical 187 
intensity signals of each spot were quantified using in-home software. Image processing 188 
(feature gridding, addressing, segmentation and quality assurance) was automatically 189 
performed in less than 5 min. 190 
 191 
Reference method 192 
Several methods for detecting somatic mutations are currently available. NGS, 193 
considered to be an optimum method for mutation detection, was conducted employing 194 
the Ion Torrent PGM technology (ThermoFisher Scientific). The Oncomine Solid Tumor 195 
DNA kit was used for DNA analysis (ThermoFisher Scientific). This assay simultaneously 196 
screens hotspots mutations in 22 genes (included PIK3CA). For generating the DNA 197 
barcoded libraries, a multiplex PCR amplification of 10 ng of genomic DNA was 198 
performed. Sequencing was performed on the Ion Torrent PGM system on a 318v2 Ion 199 
Chip using Ion PGM Sequencing Hi-Q kit (Thermo Fisher Scientific). Data from 200 
sequencing runs were transferred to the Torrent Server, alignment to the hg19 human 201 
reference genome and variant calling was performed by the Ion Torrent Suite Software 202 
5.4 (Thermo Fisher Scientific). In addition, all identified variants, such as PIK3CA 203 
mutations in exon 9 and 20 (p.E545K and p.H1047L), were visually checked using the 204 
Integrative Genomics Viewer (IGV) software. 205 




Assay design 208 
A flow diagram showing the main steps in our assay for the detection of point mutations 209 
is illustrated in Figure 1. From total genomic DNA extracted from human tissues, the 210 
target sequence is amplified following a clamp blocked RPA reaction. Compared to 211 
conventional RPA method, the reaction solution also contained an oligonucleotide 212 
complementary to wild-type DNA (blocker), the target nucleotide being in the central 213 
position of oligonucleotide. The upstream primer is in the vicinity of blocking 214 
oligonucleotide, and partially overlaps its 5’-end. The blocker oligonucleotide is designed 215 
for producing more stable complexes than upstream primer. The method operates by a 216 
competition for a common target site.  217 
 218 
Figure 1. Schematic illustration of the RPA reaction for minority allele enrichment based 219 
on the addition of blocking agent. (Up) Wild-type blocked amplification. (Bottom) Mutant 220 
amplification.  221 
 222 
The amplification mechanism of mutant variants is based on the action of recombinases 223 
(T4 uvsX and loading factor T4 uvsY), which form complexes with primers and bind them 224 
with their homologous sequences in duplex DNA [24]. A single-stranded DNA binding 225 
(SSB) protein binds to the displaced DNA strand and stabilizes the resulting D loop. Bsu 226 
polymerase (large fragment of Bacillus subtilis Pol1) produces the primer extension from 227 
the 3’-end, replicating mutant allele. The amplification of wild-type variants is impaired 228 
due to the presence of the blocking oligonucleotide. In this case, the blocking 229 
oligonucleotide dominates the binding to the template over the primer. Since the blocker 230 
also contains a chemical modification at the 3’-end, the oligonucleotide cannot be 231 
extended by Bsu polymerase. Then, the addition of this blocking agent during 232 
amplification of the target region induces the competition for the binding site in DNA 233 
template, leading to a preferential amplification of minority mutations. This clamping 234 
effect has been previously described for PCR-based methods [12,13], but this is the first 235 
time for RPA.  236 
 237 
  238 
9 
 
RPA amplification 239 
The proposed assay was tested for the genotyping of the main hotspots in PIK3CA gene 240 
(codon 542/545 and codon 1047). An in-silico design was applied for the selection of the 241 
sequence-specific primers based on the requirements established for the product 242 
properties and method performances. Compared to the conventional RPA methods, 243 
short primers (< 30 nucleotides) were selected to facilitate the subsequent allele-specific 244 
assay. Even though they had little recombinase-mediated strand-invasion activity, short 245 
primers can still function via hybridization recognition [25]. An additional design 246 
restriction was taken into account. The length of products was limited to short 247 
amplification products (lower than 100 bp). As the conservation of biopsied tissues as 248 
formalin-fixed and paraffin-embedded can lead to an important degradation of nucleic 249 
acids, this selection criteria can minimize false-negative results.  250 
Using the selected oligonucleotide sets (upstream and downstream primers), the first 251 
experiments were focused on the optimization of reaction conditions for the amplification 252 
of both hotpots in single format. Regarding kinetic behavior, the amplification process 253 
reached a stationary phase after 40 min. A similar product formation was obtained when 254 
the RPA reaction was produced within the 37-42 ºC range, showing high tolerance to 255 
temperature fluctuations. Therefore, the selected conditions were similar to previous 256 
studies for human cancer tissues [26]. 257 
RPA specificity was checked on the basis on the detection of target regions from human 258 
and non-human genomic DNA. Negative results were reported for the non-target genes 259 
or samples, demonstrating the absence of false-positive results. The matrix effect was 260 
also examined, analyzing different samples (cell culture, buccal swap, colon tissue) and 261 
storage conditions (fresh tissues and formaldehyde fixed-paraffin embedded tissues). 262 
Under the selected extraction and amplification conditions, excellent end-point 263 
amplification yields were obtained. A detectable signal was measured for 5102 DNA 264 
copies. The results were comparable to those obtained with the PCR-based method, 265 
independently on sample source (paired t-test, p-value <0.05).  266 
 267 
Selection of blocking oligonucleotides 268 
A preferential RPA-based amplification of minority mutations was studied based on the 269 
addition of a blocking oligonucleotide to the reaction solution. Following the modalities 270 
described for blocked PCR amplification, two kinds of oligonucleotide sets were assayed. 271 
The first approach, both oligonucleotides (upstream primer and blocking agent) are 272 
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complementary to different template regions, preventing the amplification in the 273 
elongation step. In the second approach, also called clamp strategy, the blocker partially 274 
overlaps with the upstream primer, reducing the amplification in the primer annealing 275 
step.  276 
As the number of possible oligonucleotides can achieve hundreds, the thermodynamic 277 
stability of DNA duplexes was examined. The parameters were the variation of free 278 
energy associated to the formation of DNA duplexes (G) and melting temperature (Tm), 279 
or temperature at which half of the blocking oligonucleotides are single-stranded state 280 
(0.1 M NaCl, 25 ºC at pH=7). Firstly, the formation of upstream primer duplexes was 281 
studied in both hotspots of PIK3CA gene. The G-values for the selected primers ranged 282 
between -19.8 kcal mol-1 and -20.5 kcal mol-1, corresponding to Tm = 58.6-60.9 ºC. 283 
Secondly, the effect of design parameters on the blocking oligonucleotide/template 284 
hybrids was estimated. Blocking agents with length higher than 22 nucleotides produced 285 
DNA complexes more stable than the selected primers (Tm>62C). The differential 286 
variation of free energy associated to the formation of DNA duplexes (wild-type vs. 287 
mutant variants) was calculated in function of clamp-region length and mutation position. 288 
The nucleotide number that overlapped with the primer produced a slight effect on the 289 
discrimination recognition for perfect match complex (wild-type template) respect to the 290 
mismatched complexes (mutant templates). However, the position of mutation on 291 
blocking agent sequence varied drastically the stability of the mismatched hybrids. In 292 
fact, the maximum difference between blockers and wild-type/mutant complexes was 293 
achieved when the mutations was located in a central position. 294 
On the basis on these experiments, several design requirements of blocking 295 
oligonucleotide were defined for blocked RPA assay (Table 1). Applying in silico 296 
calculations, two primers and a blocking oligonucleotide compose the selected set per 297 
studied mutation. The estimated G-values for wild-type complex were -23.6 kcal mol-1 298 
for exon 9 and -21.9 kcal mol-1 for exon 20, corresponding to Tm = 64.5 ºC and Tm = 63.3 299 
ºC, respectively. The selected blocking oligonucleotides should form a more stable 300 
complex with wild-type than with the mutated variant (about 4 kcal mol-1). Regarding the 301 
clamp effect, the common nucleotides (3’-end of primer and 5’-end of blocking agent) 302 
were 2 in both targeted hotspots. Under these conditions, the expected reduction of 303 
upstream primer annealing was about G = 1.9-2.0 kcal mol-1 for wild-type hybrid. 304 
Although RPA mechanism is based on the action of several enzymes, a differential 305 
behavior was expected. The blocker would preferentially hybridize onto the wild type 306 
template strand and the upstream primer would bind to the mutant template. 307 
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Table 1: (a) Design criteria of blocking oligonucleotide. (b) Optimized variables for 308 
blocked RPA. 309 
 310 
Set-up of blocked amplification  311 
The following step was the study of experimental conditions for blocked RPA, using DNA 312 
extracts from control/mutant cell lines and the selected olignucleotides. In a first set of 313 
RPA experiments, reaction mixtures contained the downstream primer and the 314 
unmodified blocker (without upstream primer). Positive responses were observed, 315 
indicating that the blocking oligonucleotide acted as upstream primer (Figure 2a). Later, 316 
the same RPA reactions were performed, including modifications at the 3’-end of the 317 
blocker (capped extension). The studied modifications were dideoxycytidine (ddC) and 318 
non-sense 3-mer tail (not complementary to template molecule), leading a signal 319 
reduction (t-test: p-value<0.002). Both chain terminator avoided the 3’-extension, 320 
yielding similar responses to negative controls, even for high concentrations of blockers 321 
(t-test: p-value>0.95). For further assays, ddC modified blocker was selected. 322 
Human genomic DNA was added in PCR and RPA reactions containing three 323 
oligonucleotides (primers and blocker) for non-clamp and clamp approaches (Figure 2b). 324 
In case of PCR, the addition of the blocker reduced the amplification of wild-type variant, 325 
the effect being higher for clamp approach. These results agreed with those previously 326 
described for PCR-based methods, where the overlapping region between primer and 327 
blocker provided better assay performances [7,8]. In case of isothermal method, using a 328 
primer complementary to a different region than blocker, the primer elongation of wild-329 
type DNA was produced (t-test: p-value = 0.89). The amplification of wild-type DNA only 330 
was reduced for clamp option (t-test: p-value = 0.01). This differential blocking effect 331 
compared to PCR agreed with the expected features of RPA mechanism. In the first 332 
approach, recombinase mediated in the formation of both complexes (primer/template 333 
and blocker/template). However, polymerase used in RPA (Bsu polymerase) has strand-334 
displacing activity that means the ability to displace downstream DNA encountered 335 
during synthesis. Although the blocking oligonucleotide was initially bound, the primer 336 
elongation was possible, replicating wild-type templates. In case of second strategy, the 337 
observed behavior fitted with a physico-chemical competition for the same template 338 
region. The blocker operates a competitor of the upstream primer for the common target 339 
site. As the stability of blocker was higher, the primer annealing in RPA process was 340 
interfered. As the non-clamp option was incompatible with RPA biochemistry, further 341 




Figure 2: (a) Modification of blocker oligonucleotide for the prevention of Bsu extension 344 
in a RPA mixture without upstream primer. Blocker concentration: 300, 600 and 800 nM. 345 
(b) Amplifications (PCR and RPA) performed in conventional and blocked formats 346 
(blocker concentration 200 nM). T-test: * p-value<0.05, ** p-value<0.01, *** p-347 
value<0.001. Wild-type genomic DNA: 1300 copies.  348 
 349 
Agarose gel electrophoresis was used for confirming the blocking effect on PCR and 350 
RPA reaction for PIK3CA (Figure SI.1). In case of PCR, the expected bands were 351 
detected (83 pb for exon 9 and 79 pb for exon 20). However, RPA products yielded 352 
smear bands due to mixture components (i.e. DNA binding proteins, detergents). 353 
Therefore, two post-amplification treatments were assayed (column purification and 354 
protein denaturation). The first method involved that silica-membrane columns retained 355 
short DNA molecules under high-salt conditions and eluted them using a low-salt buffer. 356 
The second method consisted in the denaturation of proteins at high temperature. 357 
Although both treatments provided a single band located at the estimated position, the 358 
separation obtained after heating strategy led to band intensities comparable to the PCR 359 
results. Further experiments showed that the band intensity decreased in the presence 360 
of blocking nucleotide in RPA reactions, being undetectable for high concentrations. 361 
Finally, the kinetic profile in the presence of blocker was compared to the conventional 362 
profile. Although amplification yield was lower than conventional value (about 50 %), the 363 
maximum signal was achieved after 40 min of reaction in both cases. Therefore, gel 364 
electrophoresis results proved the variation of replication activity as the consequence of 365 
blocker binding to the template. 366 
For the selection of blocker concentration, genomic DNA extracted from human cell 367 
cultures (wild-type and mutant) were amplified, varying up to 400 nM (stoichiometric ratio 368 
of 1.33 compared to the upstream primer). End-point responses decreased as the 369 
concentration of blocking oligonucleotide increased for both kind of templates (Figure 3). 370 
As the amplification variation was also observed in mutated variants, an unspecific 371 
interaction of blocker was produced in the mismatched templates. Nevertheless, certain 372 
reaction mixtures produced a nearly null signal for native variant and perfectly detectable 373 
signal for mutant variant. Experimental data fitted to a typical four-parameter logistic 374 
curve with a suitable model goodness (R2=0.94 and 0.98, exon 9 and 20, respectively). 375 
The equation of this nonlinear regression was Signal = d + (a-d)/(1+([bloq]/c)b), where 376 
[bloq] is the concentration of blocking agent, d is the background signal, a is the signal 377 
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for the absence of blocking oligonucleotide, c is related to the concentration at the 378 
inflection point and d is related to the curve steepness. Table 1 displays the estimated 379 
values for both hotspots of PIK3CA gene. Significative differences were found in the 380 
value of c-parameter that is related to half maximal effective concentration (EC50) or 381 
blocking concentration that reduced the signal to half. The EC50 values for wild-type 382 
templates were about 2 times lower than the values calculated for mutant templates for 383 
both target regions. The observed differential behavior confirmed that the addition of 384 
blocking agent produced a higher reduction of RPA reaction on perfect-match template 385 
(native) than a mismatched template (mutant). A concentration of 50 nM was selected 386 
for further experiments. 387 
 388 
Figure 3: Effect of blocking concentration on the end-point response of RPA-based 389 
methods: Reactions for exon 9 (a) and exon 20 (b). Discontinue lines correspond to the 390 
regression curve applying four-parameter logistic model. 391 
Table 2: Regression parameters obtained applying four-parameter logistic model to 392 
experimental data: blocking concentration vs. end-point response of RPA-based 393 
methods. 394 
 395 
Identification of mutations 396 
The presence of a mutation was established from the results (electrophoresis or 397 
fluorescence) for blocked RPA reactions (single format). Then, the detection of a band 398 
indicated that a mutated variant was amplified, achieving a selectivity of 100 %.  399 
The determination of the specific genetic variant needed an additional end-point method 400 
(i.e. chip hybridization, bead hybridization, among others). In the present study, a simple 401 
colorimetric microarray assay based on using allele specific probes was developed for 402 
discriminating each specific mutation for a particular hotspot (Figure SI.2). The resulting 403 
RPA amplicons were hybridized to the chip which carried probes complementary to the 404 
targeted sequence. The use of microarray detection of RPA products has been 405 
previously described in previous studies [21,27]. Nevertheless, the method was further 406 
improved to serve the purpose of integrated mutational analysis.  407 
Pursing the goal of a point-of-care test, a low-cost DNA chip combined with consumer 408 
electronic device for the readout of results, was developed. Firstly, specific probes were 409 
designed to maximize the selective recognition process, considering thermodynamic 410 
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calculations (Table SI.3). The estimated free energy variation for the complexes between 411 
the specific probes to its fully complementary target sequence varied from -21.4 to -22.4 412 
kcal mol-1 for exon 9 and from -21.7 to -22.4 kcal mol-1 for exon 20. The values calculated 413 
for mismatched complexes ranged between -14.0 to -20.0 kcal mol-1. Then, the estimated 414 
differences were large enough for a discriminatory assay. Secondly, the probe 415 
immobilization on polycarbonate chips was examined via photochemical surface 416 
activation [28,29]. Under selected conditions, the conjugation of amine-functionalized 417 
probes to carboxylate groups on chip surface produced an amide bond. The calculated 418 
immobilization probe density was 3.5 pmol cm-2. A stable and strong bound was not 419 
affected by pH, temperature or microfluidic flows (losses < 5%). 420 
Latterly, the hybridization experiments were performed by incubating the RPA products 421 
on chips with allele specific probes immobilized in microarray format. So, the 422 
discriminating elements were spatially separated, but integrated in a single assay. The 423 
optimization criteria were a high response signal for perfect-match probe and minimal 424 
response for the mismatched probes. Therefore, the mutation can be identified due to 425 
the formation of a perfect-match hybrid between the RPA product and one specific probe. 426 
The composition of hybridization solution (formamide 20 %, low ionic strength) was 427 
critical for the restrictive recognition. Another important factor was the volume of RPA 428 
product dispensed on chip. A beneficial effect of assay performed in a microarray format 429 
is the reduced distance that molecules need to travel from the bulk solution to the solid-430 
liquid interface. Selected volume (45 L) minimized the time required to obtain high spots 431 
signal, associated to shortened diffusion times. Compared to PCR chip, higher 432 
background signals were registered for RPA products. However, the signal-to-noise ratio 433 
(S/N), calculated as the ratio of the signal and the standard deviation of the background 434 
noise, was between 12 and 22. 435 
Under the selected conditions, unblocked RPA products from human cell cultures were 436 
hybridized on the chip. Given the presence of the biorecognition product, a variation of 437 
the reflection properties of chip surface was measured (Figure 4). If there was no reaction 438 
product, the maximum intensity of the reflected beam was collected (background signal). 439 
If target gene-probe recognition and subsequent solid deposit formation occurred, the 440 
light would strike the product, modifying the optical response. Wild-type products yielded 441 
a high response for their specific probes (S/N>15), and were low or null for the remaining 442 
ones (S/N<6). Mutant products of exon 9 (p.E545K) were specifically recognized for the 443 
corresponding probe (S/N = 12), since the spot signals were significantly higher than 444 
controls (t-test: p-value = 0,005). Mutant products of exon 20 (p.H1074R) hybridized to 445 
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two probes (wild-type and p.H1074R probe), giving detectable signals (S/N>15) with 446 
similar intensities (t-test: p-value = 0,07). These values agreed with a genomic DNA 447 
coming from a human cell culture that is heterozygote for this locus. Therefore, a 448 
sensitive and selective hybridization assay was achieved. The results obtained using a 449 
planar polycarbonate chip and a simple optical detection also demonstrated that the 450 
assay is compatible with a typical mass produced material and a sensing technology of 451 
DNA devices [16,22,30]. 452 
Figure 4: Probe Selectivity: spot intensity of array probes obtained from different 453 
unblocked RPA reactions and samples. Dashed line indicates control negative response. 454 
 455 
Patient analysis 456 
There were important analytical challenges associated to the mutation detection and 457 
identification related to solid cancer screening. DNA from FFPET used to determine 458 
mutation status was highly degraded due to fixation. In fact, the nature of clinical sample 459 
and the conservation mode led to low amount/poor-quality of DNA in same samples. 460 
Intact double strand DNA ranged from 10 to 270 ng L-1, with a purity 260/280nm ranged 461 
from 1.7 to 2.1. In addition, the small proportion of mutated DNA can limit the success of 462 
the assay. So, assay sensitivity was determined by preparing heterozygous mixtures 463 
with increasing percentages of mutant DNA compared to the wild-type type (Figure SI.3). 464 
These experiments emulated the wide range of clinical scenarios regarding the variable 465 
proportion of tumor cells (mutant DNA) respect to non-tumor cells (native DNA) in a 466 
biopsied sample. Experimental data was adjusted to a linear regression with an excellent 467 
model goodness (R2=0.994), indicating that blocked RPA produced a proportional 468 
amount of mutated sequences to the initial concentration of mutant genomic DNA. 469 
Mismatched DNA was detected up to 5 %, which indicated that the system was capable 470 
of detecting the mutant variant, even in low concentrations. In absence of blocker, the 471 
mutant variants were only detected when the percentage was 2-8 times higher. These 472 
results confirmed the formation of a stable duplex between blocker and wild-type 473 
template, limiting the primer hybridization and consequently producing the mutant 474 
enrichment.  475 
Intra and inter-day reproducibility, expressed as the relative standard deviation of spot 476 
intensities for the replicated assays (five replicates), were 13 % and 17 %, respectively. 477 
The ANOVA test showed that the end-point responses were comparable for the four 478 
studied genes (p-value > 0.05). 479 
16 
 
The next experiments were focused on the analysis of blind samples collected from 480 
oncological patients (formalin fixed and paraffin embedded tissues). For each sample, a 481 
blocked RPA reaction per exon was performed. The arrangement of the microarray 482 
matrixes on the chip was designed in such a way that 6 samples (4 spot replicates) would 483 
be analyzed in parallel. The incorporation of quality controls (positive and negative) 484 
helped to ensure reliable results considering the possible variation of analytical process. 485 
Examples of the obtained microarray images are shown in Figure 5. Despite of the 486 
blocked amplification, positive responses for both wild-type probes were observed in all 487 
chips (S/N 6±2). Nevertheless, a clear assignation was achieved based on the spot 488 
signals for mutant probes. Most of samples were assigned as wild-type for both studied 489 
locus (exon 9 and exon 20) because the mutant probe intensities were comparable to 490 
negative controls. The exceptions were two chips that showed a detectable response for 491 
one of the mutant probes. The S/N were 10±2 for p.E545K mutant and 17±2 for 492 
p.H1047R mutant. Therefore, patients were classified as mutant in exon 9 and mutant in 493 
exon 20, respectively. The assignations agreed with those obtained using next-494 
generation sequencing technology in all cases. However, sequencing analysis required 495 
higher amount of DNA, labor-intensive sample preparation and took longer to generate 496 
data compared with our method. The results highlighted that blocked RPA was an 497 
adequate approach since the copy number of mutated regions was high enough to be 498 
detected and discriminated in a hybridization assay. Furthermore, the proposed method 499 
fulfilled the requirements for a mutational analysis in a simple health system framework 500 
(i.e. short analysis time, low cost, and simple). 501 
 502 
Figure 5: On-chip hybridization results for oncological patient samples: (a) Microarray 503 
layout, (b) Blocked RPA for exon 9, sample: wild-type, (c) Blocked RPA for exon 9, 504 
sample: mutant p.E545K, (d) Blocked RPA for exon 20, sample: wild-type, and (e) 505 
Blocked RPA for exon 20, sample: mutant p.H1074R. 506 
 507 
CONCLUSIONS 508 
Increasing knowledge on genetic variants and availability of specific therapeutic agents 509 
is enabling the development of a more personalized oncogenic medicine (e.g. specific 510 
monoclonal antibodies). However, a parallel technological development is required for 511 
translating them to clinic routine. Real-time PCR, droplet digital PCR and DNA 512 
sequencing are the most widely used method for mutational analysis. Although this 513 
objective has been effectively addressed, they involve a labor-intensive expensive 514 
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solution or a limited capability in multiplex analysis. This study is aligned with the 515 
research line of developing alternative solutions. 516 
RPA-based methods are a successful approach for supporting portable diagnostic DNA 517 
assays due to their performances. However, this study is the first in demonstrating that 518 
blocked RPA is an adequate mutant enrichment technique. The results have shown that 519 
this blocking behavior is a less effective process compared to other approaches, but the 520 
achieved sensitivity (about 5 %) and reproducibility (about 15 %) are enough for their 521 
application to biopsied samples in solid tumors.  522 
The other relevant issue approached in this study is the discrimination of point mutations. 523 
In large hospitals, several methods are applied for determining the presence of a 524 
mutation in certain locus, without identifying the specific variant. Others perform a 525 
reaction per each mutation. The consequences are a lack of information limiting the 526 
possibilities of modern oncology or an increase of laboratory efforts, reducing the 527 
sustainability of the health system. Chip-based detection approaches, such as we have 528 
introduced, show the advantage of multiplexing. All investigated variants can be 529 
implemented on the same microarray. In addition, the inclusion of controls guarantees 530 
the assay reliability. Indeed, the optimized protocol is faster (performed in less than 2.5 531 
h) and easier to handle than sequencing.  532 
According to the amplitude of described applications based on blocked PCR, the 533 
expectations of the blocked RPA are high. Furthermore, the method can potentially 534 
support the detection/discrimination of mutations in more health scenarios (e.g. small 535 
hospital or clinics). Demonstrated for PIK3CA mutational analysis, the next experimental 536 
activities are addressed to expand to other mutations. Then, a better stratification of 537 
patients, or division of patients into subgroups based on the molecular characteristics, 538 
can be achieved and a subsequent individualized treatment can be assigned.  539 
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TABLE 2 688 
    a b c d R2 
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